Condition: Advanced Solid Tumors · Refractory Lymphoma · Relapsed Hematologic Malignancy · Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2005 in patients with relapsed/refractory B-cell lymphoma and advanced solid tumors.
This description comes directly from the study's public registry record.
Jun Zhou, Master · 18061872796 · hdgdzhoujun@eastchinapharm.com
Always discuss trial participation with your own doctor first.
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| The Second Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou, Jiangsu, China | Recruiting |
| The First Affiliated Hospital Of Nanchang University | Nanchang, Jiangxi, China | Not Yet Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Not Yet Recruiting |
| The First Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Not Yet Recruiting |
| The Institute of Hematology and Blood Diseases Hospital at the Chinese Academy of Medical Sciences | Tianjing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06615193